Abstract: The present invention relates to an orally disintegrating tablet including a benzimidazole derivative compound and a preparation method thereof.

Abstract: The present disclosure relates to a pharmaceutical composition containing a benzimidazole derivative compound. Specifically, the present disclosure relates to a formulation capable of maintaining a sustained blood concentration of the benzimidazole derivative compound.

Abstract: The present disclosure relates to a pharmaceutical composition that delayed-releases tegoprazan and releases clopidogrel immediately. The pharmaceutical composition may exhibit significantly excellent effects on the prevention and treatment of gastrointestinal disorders caused by administration of clopidogrel and thrombosis-related diseases.

Abstract: Disclosed herein is a method of preparing a nanoporous organic-inorganic hybrid film. The method includes preparing an organic sol including a compound having amino groups, a compound having isocyanate groups, and a solvent; adding an inorganic oxide precursor to the organic sol to form a mixed solution; and subjecting the mixed solution to heat treatment to form an organic molecule network structure in which the organic sol is gelled, and an inorganic molecule network structure located along a surface of the organic molecule network structure.

Abstract: The present invention relates to a gastric-retention type sustained-release formulation of metformin as an insulin-independent diabetic agent, and a preparation method thereof. More specifically, the present invention relates to a gastric-retention type sustained-release formulation, which can effectively control drug release even with a small amount of a polymer by forming a sustained-release granulated material, which comprises granules containing metformin or a pharmaceutically acceptable salt thereof and a swellable polymer, and a water-insoluble coated on the surface of the granules; and also can allow a tablet containing the drug to swell rapidly at an early stage by formulating via mixing of a superdisintegrant, which is capable of controlling the speed of gelation forming hydrogels, with the granulated material; and a preparation method thereof.

Abstract: Disclosed herein is a method of preparing a nanoporous organic-inorganic hybrid film. The method includes preparing an organic sol including a compound having amino groups, a compound having isocyanate groups, and a solvent; adding an inorganic oxide precursor to the organic sol to form a mixed solution; and subjecting the mixed solution to heat treatment to form an organic molecule network structure in which the organic sol is gelled, and an inorganic molecule network structure located along a surface of the organic molecule network structure.

Abstract: Provided are a semiconductor chip package and a method of manufacturing the same. The semiconductor chip package includes a semiconductor chip comprising a chip pad, and a rerouting layer disposed on the semiconductor chip and including a metal interconnection electrically connected to the chip pad and a partial oxidation region formed by the oxidation of metal and insulating the metal interconnection.

Abstract: Provided is a pharmaceutical composition including clopidogrel bisulfate and a pregelatinized starch. The pharmaceutical composition in which the stability of clopidogrel bisulfate is significantly enhanced can be obtained by mixing clopidogrel bisulfate with the pregelatinized starch.

Abstract: Disclosed is a multiple unit type sustained release oral formulation comprising sustained release pellets formed from granules containing an active ingredient and a water-insoluble polymer, the granules being coated with a sustained release base material; and rapid release granules containing the active ingredient, and a method for preparing the same.

Abstract: Disclosed is a zaltoprofen-containing sustained release tablet comprising granules containing zaltoprofen and a binder, in which the granules are dispersed in a matrix comprising a hydrophilic polymer, and a diluent is present either in the granules or in the matrix.

Abstract: Disclosed is a stable pharmaceutical solution preparation of erythropoietin (EPO), which includes a stabilizing agent not containing a blood-derived protein, thereby maintaining EPO activity for a prolonged period of time without the risk of viral contamination. The stable solution preparation further includes a non-ionic surfactant and a tonicity agent, thereby preventing EPO loss during storage and facilitating administration to the body.